Key terms
About BTAI
BioXcel Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of artificial intelligence solutions in neuroscience and immuno-oncology. It also focuses on utilizing technology and research to develop therapeutics solutions. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest BTAI news
May 14
5:07am ET
Hold Rating on Bioxcel Therapeutics Amid Growth Potential and Financial Uncertainties
May 10
6:47am ET
Bullish Outlook: Bioxcel Therapeutics’ Revenue Surge and Promising Clinical Trials Fuel Buy Rating
May 09
7:24am ET
BioXcel Therapeutics reports Q1 EPS (87c), consensus (70c)
Apr 26
2:11am ET
Hold Rating on Bioxcel Therapeutics Amid Strategic and Clinical Trial Uncertainties
Apr 23
6:25am ET
Buy Rating Reaffirmed for BioXcel Therapeutics Amidst Expansion Opportunities and FDA-Approved IGALMI™
Apr 22
7:22am ET
Bioxcel Therapeutics Advances SERENITY Trial and Strategy
Apr 22
7:12am ET
BioXcel announces plan for evaluating BXCL501 in at-home setting
Apr 16
6:31am ET
Analysts Offer Insights on Healthcare Companies: Bioxcel Therapeutics (BTAI) and Unity Biotechnology (UBX)
Apr 16
6:30am ET
Analysts Offer Insights on Healthcare Companies: Icecure Medical (ICCM), Viracta Therapeutics (VIRX) and Bioxcel Therapeutics (BTAI)
Apr 15
6:48am ET
BioXcel Therapeutics price target lowered to $10 from $11 at H.C. Wainwright
Apr 15
6:16am ET
Buy Rating Affirmed for Bioxcel Therapeutics Amid Strategic Clinical Trials and Regulatory Potential
Mar 25
7:13am ET
BioXcel Therapeutics announces $25M registered direct offering
Mar 24
2:01am ET
Bioxcel Therapeutics Faces Market Estimation Risks Amidst Adoption and Access Challenges
Mar 19
8:45am ET
Largest borrow rate increases among liquid names
Mar 18
6:26am ET
Buy Rating Affirmed for BioXcel Therapeutics: FDA Pathway Clear for BXCL501 Expansion
Mar 15
8:45am ET
Largest borrow rate increases among liquid names
Mar 15
7:09am ET
BioXcel Therapeutics announces European Patent Office grant
Mar 13
7:32am ET
BioXcel Therapeutics price target lowered to $7 from $8 at BofA
Mar 13
6:39am ET
Buy Rating Affirmed for BioXcel Therapeutics Amid Label Expansion and Strong Clinical Prospects
Mar 12
8:05am ET
Options Volatility and Implied Earnings Moves Today, March 12, 2024
Mar 12
7:09am ET
BioXcel Therapeutics provides updates on clinical programs for BXCL501
Mar 12
7:07am ET
BioXcel Therapeutics expects cash to fund operations through mid-2024
Mar 12
7:07am ET
BioXcel Therapeutics reports Q4 EPS (76c), consensus (91c)
Mar 01
8:45am ET
Largest borrow rate increases among liquid names
Feb 28
8:45am ET
Largest borrow rate increases among liquid names
Feb 21
7:26am ET
BioXcel Therapeutics downgraded to Neutral from Buy at UBS
No recent press releases are available for BTAI
BTAI Financials
Key terms
Ad Feedback
BTAI Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
BTAI Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range